TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Maintains Target Price $10
TD Cowen Initiates Ginkgo Bioworks(DNA.US) With Buy Rating, Announces Target Price $10
Ginkgo Bioworks Holdings: A Buy Rating on Strategic AI Advancements and Market Expansion
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Maintains Target Price $7
Ginkgo Bioworks Holdings Analyst Ratings
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Cuts Target Price to $7
Ginkgo Bioworks Holdings: Sell Rating Affirmed With Revised Valuation and Price Target
Morgan Stanley Maintains Ginkgo Bioworks(DNA.US) With Hold Rating, Maintains Target Price $40
Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA) and LifeMD (LFMD)
Ginkgo Bioworks: Hold Rating Maintained Amid Revenue Uncertainty and Restructuring Challenges
Ginkgo Bioworks: Underperform Rating Due to Financial Strain and Uncertain Strategic Outcomes
Ginkgo Bioworks Holdings Analyst Ratings
Ginkgo Bioworks Holdings Analyst Ratings
Ginkgo Bioworks Holdings Analyst Ratings
Ginkgo Bioworks Holdings Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Zoetis (ZTS) and Ginkgo Bioworks Holdings (DNA)
Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA), ZimVie Inc (ZIMV) and Veeva Systems (VEEV)
Ginkgo Bioworks Holdings Analyst Ratings
Buy Rating Affirmed for Ginkgo Bioworks Amidst Strategic Growth and Diversification
Ginkgo Bioworks Holdings Analyst Ratings